1. Pink Sheet
  2. >>Compliance
  3. >>Marketing & Advertising

Insys Must Divest Subsys, Buprenorphine Candidate Products As Part Of Corporate Integrity Agreement

 
• By Derrick Gingery

Settlement with US government also includes $225m payment to resolve criminal and civil cases related to illegal marketing of the sublingual fentanyl spray Subsys.

LISBON, PORTUGAL - December 9, 2014: Photo of the United States Department of Justice (DOJ) homepage on a monitor screen through a magnifying glass.
Insys must exit the opioid space as part of a corporate integrity agreement negotiated with the US Justice and Health and Human Services departments. • Source: Shutterstock

Insys Therapeutics Inc. must divest the opioid product at the center of kickback charges by company executives and a federal False Claims Act case, an apparently unprecedented move by the government.

Within the 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

More from Compliance